Uniqure NV (NASDAQ:QURE) – Stock analysts at B. Riley lowered their FY2018 earnings per share estimates for Uniqure in a research note issued to investors on Wednesday, November 7th. B. Riley analyst M. Kumar now forecasts that the biotechnology company will post earnings of ($2.23) per share for the year, down from their previous forecast of ($2.22). B. Riley also issued estimates for Uniqure’s Q4 2018 earnings at ($0.67) EPS, Q1 2019 earnings at ($0.88) EPS, Q2 2019 earnings at ($0.88) EPS, Q3 2019 earnings at ($0.88) EPS, Q4 2019 earnings at ($0.88) EPS, FY2019 earnings at ($3.50) EPS, FY2020 earnings at ($3.43) EPS and FY2021 earnings at ($0.47) EPS.
Several other research analysts have also commented on the stock. Chardan Capital lifted their price target on shares of Uniqure from $50.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright set a $48.00 price target on shares of Uniqure and gave the company a “buy” rating in a report on Wednesday. BidaskClub raised shares of Uniqure from a “sell” rating to a “hold” rating in a report on Friday, October 19th. Zacks Investment Research lowered shares of Uniqure from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. Finally, Cantor Fitzgerald set a $58.00 price target on shares of Uniqure and gave the company a “buy” rating in a report on Wednesday, October 3rd. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Uniqure has a consensus rating of “Buy” and a consensus target price of $49.67.
NASDAQ QURE opened at $25.72 on Friday. Uniqure has a one year low of $13.71 and a one year high of $43.23. The company has a quick ratio of 8.36, a current ratio of 7.56 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $1.04 billion, a PE ratio of -8.75 and a beta of 0.78.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.03. Uniqure had a negative net margin of 725.04% and a negative return on equity of 58.49%. The business had revenue of $3.15 million during the quarter, compared to analyst estimates of $3.37 million.
A number of institutional investors have recently bought and sold shares of QURE. California Public Employees Retirement System acquired a new position in Uniqure during the 1st quarter valued at about $332,000. Jane Street Group LLC acquired a new position in Uniqure during the 1st quarter valued at about $224,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Uniqure by 276.5% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 4,700 shares during the period. Atria Investments LLC acquired a new position in Uniqure during the 2nd quarter valued at about $247,000. Finally, Fred Alger Management Inc. acquired a new position in Uniqure during the 2nd quarter valued at about $983,000. 59.10% of the stock is owned by hedge funds and other institutional investors.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Read More: What is a Reverse Stock Split?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.